BSEM: Record Revenue Makes This a High-Growth MedTech Opportunity!

Record revenues, insider conviction, and robust cash reserves make this a rare opportunity ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Huge Alerts. BioStem Technologies (BSEM) Surges Ahead with Record Revenues, Insider Buying, and Breakthrough Clinical Pipeline—Could This Be the Next Big Winner in MedTech? BioStem Technologies Inc. (OTC: BSEM) is redefining the future of regenerative medicine and wound care—and the market is starting to take notice.  The company develops groundbreaking therapies designed to accelerate healing in chronic and complex wounds, including diabetic foot ulcers and venous leg ulcers. Its flagship VendajeAC line and expanding portfolio of advanced regenerative products are winning rapid adoption across hospitals, clinics, and specialty care centers, fueling a massive surge in revenue.  In Q2 2025, BioStem posted preliminary Q2 2025 results, generating $49.3 million in net revenue and achieving the sixth consecutive quarter of positive adjusted EBITDA at $2.5 million. Cash reserves increased to $30.8 million, up $4.1 million from the previous quarter.  Key business developments include the appointment of Brandon Poe as CFO, completion of enrollment in a pivotal clinical trial for BioREtain® Amnion Chorion targeting diabetic foot ulcers (with data expected in Q4 2025), expansion of the commercial organization to access new sites of care, and growth of the intellectual property portfolio to 58 issued patents and 68 pending.  The excitement doesn’t stop there. BSEM insiders are snapping up shares, signaling strong confidence in the company’s near-term upside, while its clinical pipeline accelerates with pivotal trials for diabetic foot ulcers and new studies for venous leg ulcers.  And with a potential uplisting to a senior stock exchange under review, BSEM is on the brink of massive visibility and market recognition.  This combination of record revenues, insider conviction, robust cash reserves, and cutting-edge therapies makes BioStem Technologies one of the rare high-growth MedTech opportunities out there.  With insider buying, pivotal clinical trials nearing data readouts, and a potential uplisting to a senior stock exchange on the horizon, see how BSEM is perfectly positioned for explosive growth and market recognition.  We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists of up to $5,500 and was received/will be received from Sideways Frequency. This compensation should not be considered as an endorsement of the securities of BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 9/29/2025. Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. Behind the Markets You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.   Today's Bonus Content: 10 EV Stocks to Buy in September (By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time. - Privacy Policy)